Skip to main content
. Author manuscript; available in PMC: 2017 Aug 28.
Published in final edited form as: Tumour Biol. 2015 Feb 11;36(7):5505–5513. doi: 10.1007/s13277-015-3218-4

Figure 3.

Figure 3

Comparison of the mean fluorescent intensity (MFI) in HER2 amplified cell line ARK 2 after treatment with dacomitinib at a concentration of 0.140μM in different time course for phosphorylated HER2 (a) and S6 (b). Comparison of the MFI in cell line ARK-2 after 8 hours exposure to different dose of dacomitinib for phosphorylated HER2 (c) and S6 (d).